Skip to product information
1 of 1


RespiSure-250 Dose

RespiSure-250 Dose

Regular price $88.95 USD
Regular price Sale price $88.95 USD
Sale Sold out
Shipping calculated at checkout.

SIze: 250 Dose

Highly antigenic whole cell inactivated Mycoplasma hyopneumoniae bacterin. Adjuvanted with Amphigen to enhance and prolong the immune response without causing detectable tissue damage at injection site.

Dosage: Shake well and inject IM. Pigs - 2 ml at 1 week, repeat in 2 weeks; Sows - 2 ml at 6 weeks and 2 weeks prior to farrowing. Revaccinate annually. 21-day slaughter withdrawal.

Manufacturer and/or Label Information

Telephone: 269-359-4414
Customer Service: 888-963-8471
THIS SERVICE AND DATA ARE PROVIDED "AS IS". DVMetrics assumes no liability, and each user assumes full risk, responsibility, and liability, related to its use of the DVMetrics service and data. See the Terms of Use for further details.


Mycoplasma Hyopneumoniae Bacterin

U.S. Vet. Lic. No.: 190

Description: RESPISUREĀ® contains a chemically inactivated whole cell culture of M. hyopneumoniae, coupled with an oil adjuvant, AmphigenĀ®, to enhance and prolong the immune response without causing detectable tissue damage at the injection site.

Indications: RESPISUREĀ® is for vaccination of healthy swine as an aid in the prevention of chronic pneumonia caused by Mycoplasma hyopneumoniae.


1. General Directions: For best results, vaccination of all swine in a herd is recommended. Shake well. Aseptically administer two 2-mL doses intramuscularly, at least 2 weeks apart.

2. Primary Vaccination: Administer a single 2-mL dose to pigs at approximately 1 week of age with a booster dose 2 weeks later. Pregnant swine may be safely vaccinated at 6 weeks and 2 weeks prior to farrowing.

3. Revaccination: Dams should be revaccinated 2 weeks before farrowing. Boars should be revaccinated semiannually.

Precaution(s): Store at 2Ā°-7Ā°C. Prolonged exposure to higher temperatures may adversely affect potency. Do not freeze. Use entire contents when first opened. Sterilized syringes and needles should be used to administer this vaccine.

Caution(s): As with any vaccine, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.

This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.

For use in swine only.

Warning(s): Do not vaccinate within 21 days before slaughter.

For veterinary use only.

Discussion: Disease Description: Mycoplasmal pneumonia of swine (MPS), or enzootic pneumonia, is a widespread, chronic disease characterized by coughing, growth retardation, and reduced feed efficiency. The etiologic agent is M. hyopneumoniae; however, the naturally occurring disease often results from a combination of bacterial and mycoplasmal infections.

MPS causes considerable economic loss in all areas where swine are raised. Surveys conducted at various locations throughout the world indicate that lesions typical of those seen with MPS occur in 30% to 80% of slaughter-weight swine. Because mycoplasmal lesions may resolve before hogs reach slaughter weight, the actual incidence may be higher. The prevalence of M. hyopneumoniae infection in chronic swine pneumonia has been reported to range from 25%1 to 93%.2 Research indicates that MPS infections can add up to 30 days to market and increase feed consumption by 0.75 lb per lb of weight gain.

Pigs of all ages are susceptible to MPS, but the disease is most common in growing and finishing swine. Current evidence indicates the M. hyopneumoniae is transmitted by aerosol or direct contact with respiratory tract secretions from infected swine. In some cases, transmission has been attributed to carrier pigs, but other evidence demonstrates that transmission among penmates can occur once a few pigs are infected.3-4 Transmission from sow to pig during lactation is possible.5 Once established, MPS occurs year after year in affected herds, varying in severity with such environmental factors as season, ventilation, and concentration of swine.

Clinical signs of MPS include a chronic nonproductive cough continuing for weeks or months, unthrifty appearance, and retarded growth, even though the appetites of infected swine remain normal. Stunting may occur, resulting in considerable variation in size among affected pigs. Death loss associated with secondary bacterial infection and stress may occur at 4-6 months of age.

M. hyopneumoniae causes a loss of ciliary motility in the bronchial passages. Eventually the cilia are destroyed, resulting in a reduction in natural defense in the upper respiratory tract and increased susceptibility to secondary infection with bacterial agents such as Pasteurella multocida, Haemophilus parasuis, Actinobacillus pleuropneumoniae, and Bordetella bronchiseptica. Swine lungworm and roundworm larvae infections may also increase the severity of MPS.

Trial Data: Safety and Efficacy: Chemical inactivation renders RESPISUREĀ® incapable of causing infectious disease. Necropsy data from in-house clinical trials showed that tissue damage occurred at only 6 (1.87%) of 320 injection sites, and none of the reactions were larger than 1 cm in diameter. The oil-base adjuvant in RESPISUREĀ® does not produce the major tissue damage sometimes associated with conventional oil adjuvants.

Efficacy of RESPISUREĀ® was evaluated in rigorous challenge-of-immunity studies. In repeated studies, RESPISUREĀ® vaccinates had between 72% and 92% less lung involvement caused by homologous and heterologous challenge strains of M. hyopneumoniae than controls. In 2 such tests, vaccinates received 2 intramuscular doses of bacterin, the first at 1 week of age, the second at 3 weeks. One week after the second vaccination, 1 group of vaccinated and nonvaccinated control pigs were challenged intranasally with a homologous strain of M. hyopneumoniae culture, the second group with a heterologous strain. About 3 weeks after challenge, all pigs were necropsied and individual lungs were evaluated for lung damage and gross lesions characteristic of M. hyopneumoniae infection and scored according to a system devised by Goodwin and Whittlestone.6 Results are presented in Figures 1 and 2.

Figure 1. Mean percentage of lung damage following challenge with homologous M. hyopneumoniae.

Figure 2. Mean percentage of lung damage following challenge with heterologous M. hyopneumoniae.

In pigs challenged with the homologous strain, the mean percentage of lung damage was 4.98% in vaccinates and 27.91% in controls (an 82.16% reduction in lung damage in vaccinates when compared to controls). Mean lung damage score for pigs challenged with the heterologous strain was 1.81% for vaccinates and 19.24% for controls (a 90.6% reduction in lung damage in vaccinates when compared to controls).

In an independent challenge-of-immunity study conducted at Iowa State University, pigs vaccinated at approximately 6 weeks and again at 8 weeks of age with RESPISUREĀ® showed evidence of less severe M. hyopneumoniae infection (1.9% mean percentage of lung damage) than nonvaccinated control pigs (7.9% mean percentage of lung damage), a 75.91% reduction in lung damage in vaccinates when compared to controls (p = <0.01). Vaccinates also had fewer lung lobes with lesions (6 of 9 vaccinates had lesions in 12 of 63 lobes) than controls (8 of 8 had lesions in 35 of 56 lobes), and the lesions were less severe.

Evaluation of lung tissue and lesions by fluorescent antibody (FA) testing revealed that 7 of 8 control pigs and 3 of 9 vaccinates were positive for M. hyopneumoniae. Based on a system rating the intensity of infection in lung lobes as measured by immunofluorescence from 1-4, the severity of vaccinates' infections (average 0.18) was 71% less than that of controls (average 0.63) (Figure 3).

Figure 3. Severity of lung infection as measured by immunofluorescence following challenge with M. hyopneumoniae (0=no infection).

References: Available upon request.


Presentation: 50 dose (100 mL), 250 dose (500 mL), and 500 dose (1,000 mL) vials.

CPN: 3690037.2

COLORADO SERUM COMPANY4950 YORK STREET, P.O. BOX 16428, DENVER, CO, 80216-0428Telephone:Ā 303-295-7527Order Desk:Ā 800-525-2065Fax:Ā 303-295-1923Website:Ā www.colorado-serum.comEmail:Ā colorado-serum@colorado-serum.comTHIS SERVICE AND DATA ARE PROVIDED "AS IS". DVMetrics assumes no liability, and each user assumes full risk, responsibility, and liability, related to its use of the DVMetrics service and data. See the Terms of Use for further details.


Colorado Serum


GENERAL INFORMATION:Ā This product has been shown to be effective for the vaccination of healthy horses, cattle, sheep, goats, and swine against tetanus. This product was licensed prior to the requirement to establish a minimum age for use. The duration of immunity is unknown. For more information regarding efficacy and safety data, see

Safety in pregnant animals is unknown.

Tetanus Toxoid is prepared by detoxifying tetanus toxin in such a manner as to allow the antigenic properties to remain intact. Product is purified, concentrated and adjuvanted to provide a low dose effective immunizing agent.

Each serial is tested for purity, safety, and potency in accordance with USDA requirements.

Tetanus is caused by a neurotoxin produced by growth ofĀ Clostridium tetani, an anaerobic (lives without air) micro-organism, in necrotic tissue. Affected animals become stiff, have difficulty swallowing, and have an increased pulse rate. Breathing is labored. Spasmodic contractions of the muscular system occur, such as contracting muscles of the jaw.

Spasmodic contractions of the muscular system occur, such as contracting muscles of the jaw. Thus, the term ā€œlockjawā€ is often used. Legs and tail are often stiff with abdominal muscles contracted. Tetanus stricken animals may be unusually sensitive to light and heat. Temperature of the animal generally remains normal, elevating only shortly before death.

Protective antibody levels usually occur about two weeks after the second injection of the primary immunization series. In contrast, administration of Tetanus Antitoxin is recommended for immediate, emergency, passive treatment of exposed animals with unknown vaccination history or with signs of tetanus infection.

DIRECTIONS:Ā Do not vaccinate within 21 days before slaughter. Store at 2-8Ā°Ā C. Do not freeze. Do not mix with other products. Shake well before use. Use entire contents when first opened.

PRECAUTIONS:Ā A transitory local reaction may occur at injection site. Anaphylactoid reaction may occur following administration of products of this nature. If noted, administer adrenalin or equivalent. In case of human exposure, consult a physician.

DOSAGE & ADMINISTRATION:Ā For primary immunization, two doses should be administered subcutaneously or intramuscularly approximately 30 days apart. Use intramuscularly for horses as local reactions are more likely to occur if injected subcutaneously.

Horses:Ā 1 ml IM

Cattle:Ā 1 ml SC or IM

Sheep, Goats, Swine:Ā 0.5 ml SC or IM

Historically, annual single dose revaccination has been recommended. Contact veterinarian for advice.

OTHER INFORMATION:Ā Contains thimerosal and formalin as preservatives. Tetanus Toxoid Concentrate is available in single dose size packaged 10 vials to the carton, and in 10 dose vials.


VLN: 188 / PCN: 8601.00

COLORADO SERUM COMPANY, 4950 York Street, Denver, Colorado 80216


Contact us for information on other Colorado Serum Company products. Fine Veterinary Products since 1923.




Order #

10 - 1 ml vials

10 - 1 dose vials


10 ml

10 doses


CPN:Ā 1101033.3


Care information

View full details